Novartis AG, of Basel, Switzerland, said the FDA approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives. The new use is for patients 12 years and older who remain symptomatic despite treatment with H1-antihistamine therapy.